| | |
|
| |
| | |
|
|
Hydrolyzed Collagen (Chicken) Type 2 100 Grams
|
|
ADP: $29.99
Price: $6.99
You Save: $23.00 (77 %)
In stock
Manufacturer: *Supplement Direct*
Manufacturer Part No: 734891030937
|
Supplement Direct COLLAGEN TYPE II Chicken collagen derived from the sternum of chickens. Type II collagen is the most abundant collagen found in hyaline cartilage (in synovial joints, sternum, respiratory tract), comprising 80 to 90% of the total collagen content. Chicken collagen II is also known as type II chicken collagen and is abbreviated as CCII. Type II chicken collagen shares some similar antigenic regions with type II human collagen. Autoimmune response to type II collagen is thought to be a significant factor in the pathogenesis of rheumatoid arthritis. A few studies suggest that oral type II chicken collagen may be beneficial to some with rheumatoid arthritis, acting by a process known as oral tolerance.
Suggested Use: Take 1-2 servings 1-2 times daily preferably prior to breakfast and dinner. Supplement Facts: Serving Size: 1 level teaspoon ( approx: 250 MG), Servings Per Container: 400, Calories: 0 Protein 0: Total Fat 0, Saturated Fat 0 grams, Cholesterol 0 grams, Sodium 0 grams, Potassium 0 grams, Total Carbohydrates 0 grams, Dietary Fiber 0 grams, sugars 0 grams, Protein 0 grams, not a significant source of any vitamins.
Ingredients: Chicken Collagen Type II
Manufactured and Distrubuted by: SUPPLEMENT DIRECT 6000 S EASTERN 14G LAS VEGAS, NV 89119 TELEPHONE SUPPORT 805-441-8130
RESEARCH
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
OBJECTIVE: Oral administration of cartilage-derived type II collagen (CII) has been shown to amelioratearthritis in animal models of joint inflammation, and preliminary studies have suggested that this novel therapy is clinically beneficial and safe in patients with rheumatoid arthritis (RA). The present study was undertaken to test the safety and efficacy of 4 different dosages of orally administered CII in patients with RA.
METHODS: Two hundred seventy-four patients with active RA were enrolled at 6 different sites and randomized to receive placebo or 1 of 4 dosages (20, 100, 500, or 2,500 microg/day) of oral CII for 24 weeks. Efficacy parameters were assessed monthly. Cumulative response rates (percentage of patients meeting the criteria for response at any time during the study) were analyzed utilizing 3 sets of composite criteria: the Paulus criteria, the American College of Rheumatology criteria for improvement in RA, and a requirement for > or = 30% reduction in both swollen and tender joint counts.
RESULTS: Eighty-three percent of patients completed 24 weeks of treatment. Numeric trends in favor of the 20 microg/day treatment group were seen with all 3 cumulative composite measures. However, a statistically significant increase (P = 0.035) in response rate for the 20 microg/day group versus placebo was detected using only the Paulus criteria. The presence of serum antibodies to CII at baseline was significantly associated with an increased likelihood of responding to treatment. No treatment-related adverse events were detected. The efficacy seen with the lowest dosage is consistent with the findings of animal studies and with known mechanisms of oral tolerance in which lower doses of orally administered autoantigens preferentially induce disease-suppressing regulatory cells.
CONCLUSION: Positive effects were observed with CII at the lowest dosage tested, and the presence of serum antibodies to CII at baseline may predict response to therapy. No side effects were associated with this novel therapeutic agent. Further controlled studies are required to assess the efficacy of this treatment approach.
|
|
Product Reviews
| (23 Ratings, 0 Reviews) |
Average Rating:
|
|
|
|